Novo blinked.

Here is a number that should not exist.

Novo Nordisk, the company that built the biggest drug category on earth, told investors in February to expect sales to fall 5 to 13% this year, then narrowed the range to 4 to 12% in May. First decline of its GLP-1 era. In the same February week, Eli Lilly guided to 27% growth.

Two years ago Novo had a monopoly. Now it has a court date.

Because yesterday, Novo sued Lilly. Federal court, New Jersey. The claim: Lilly’s ads compare Lilly’s highest doses against Wegovy’s lower ones, using a head-to-head trial that Novo says is out of date now that high-dose Wegovy is approved. Lilly’s response, roughly: we ran the trial, we won it, see you in court.

Maybe Novo is right on the law. Doesn’t matter. Read the scoreboard instead. Market leaders publish trial data. Companies losing share sue about it.

What actually changed

Not demand. Demand is fine. Roughly one in eight American adults has now used one of these drugs, and the number that matters is still going up.

What died is pricing power. Look at the staircase:

channel	per month
Wegovy, brand, Canada, 2025	$540
Direct cash channels, US	$149 to $399/mo
Generic semaglutide, Canada, today	$88 at Costco
Three or more generics listed	roughly 35% of brand, pending

Same molecule, top to bottom. The only difference is the year and the border.

Canada’s exclusivity ran out first, in January. Generics hit pharmacies in May. The US does not get generic semaglutide until the 2030s, which means Canada is running the ending of this movie while America is still in act two. We will be reporting from up here regularly. Consider it a preview of your future.

Then there is the pill. Lilly’s orforglipron launched this year at $149 a month. No needle, no fridge, no ceremony. Every person who would never inject themselves just became a customer. The funnel got wider and the price got lower on the same day, which is wonderful for patients and brutal for anyone whose spreadsheet assumed $500 a month forever.

$88

That is what “Novo blinked” means. Volume can keep growing while revenue falls. That is not a paradox. That is what a commodity looks like being born.

Who gets hurt

Novo first, but not worst. The margin damage prints on earnings day. The strategic damage is quieter: Novo spent a decade building a category it no longer controls, and its 2026 playbook so far is a price cut, a higher dose, and a lawsuit. Those are all defense.

The telehealth wrappers, worst. Their business was access: get a prescription fast, get the drug cheap. Except pharma now sells direct, the FDA is shutting down the compounding loophole that made “cheap” possible, and the $149 pill ships through their own storefronts at margins that would embarrass a gas station. Hims spent February fighting a Novo patent suit that ended in March as a supply partnership. When access becomes a commodity, an access company needs a new answer to “what are you for.”

The quiet losers: payers. Employers and insurers wrote coverage policies assuming these prices hold. Most patients regain the weight when they stop, so every coverage decision is quietly a forever decision. Falling prices help, but “cheaper forever” is still forever. Watch the plan-design fights. That is where this lands next.

Watching for

• Sevmia’s price. Canada approved the first generic of Wegovy itself on June 29 and has not published the number. It is the most interesting missing number on this beat.
• Orforglipron’s first price cut. $149 is an opening bid, not a floor.
• Lilly’s next move: fight the suit loudly, or settle quietly and keep taking share.

That is the brief. Same time Friday.

Updated July 28, 2026: the US direct-channel row now reflects semaglutide products only; an earlier version mixed in tirzepatide vial pricing. Prices move; the corrections will always be here.

Updated August 9, 2026: the Hims legal status is corrected; the February patent suit was dismissed in March alongside a Novo supply collaboration we had not yet filed.